RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES 11 The following table sets forth the cost for our research and development for the fiscal years ending December 31, 2016 and 2017: As of December 31, 2016 2017 (K€) (K€) Personnel expenses (1) 4,375 4,734 Sub-contracting, collaboration and consultants 11,358 11,672 Licensing and intellectual property 1,075 155 Real estate property rental, net 615 516 Conferences and travel expenses 815 1,065 Allowance for amortization and depreciation 173 184 Others 118 348 Total R&D expenses 18,529 18,675 (1)Includes €1.8 million and €1.5 million related to share-based compensation expense for 2016 and 2017, respectively. 11.3 • Luk H. Vandenberghe, Ph.D., is Assistant Professor at Harvard MEDICAL AND SCIENTIFIC COMMITTEE Medical School and runs an active research laboratory at the Massachusetts Eye and Ear Infirmary and the Schepens Eye In addition to our own research and development teams, we Research Institute. He directs the Grousbeck Gene Therapy have a Scientific Advisory Board comprised of seven renowned Center which is focused on the biology of somatic gene transfer, scientists from different countries who are opinion leaders in the development of enabling technologies in gene therapy and their specialities and Key assets to our business. The function the translation of clinical programs with a particular emphasis of the Scientific Advisory Board is to identify new technological on vision and hearing restoration. advances that may be of interest for our business. • Professor Ernst Bamberg is Professor of Biophysical Since our inception, our Scientific Advisory Board has been Chemistry at University of Frankfurt, and Director of the comprised of the following members: Department of Biophysical Chemistry of the Max Planck • Dr. Botond Roska (Chairman of our Scientific Advisory Institute für Biophysik in Frankfurt. Pr. Bamberg is the inventor Board) is senior group leader at the Friedrich Miescher Institute of the optogenetics approach and has been at the fore front of in Basel, Switzerland. Dr. Roska was educated at the University this technology since its discovery. of California Berkeley, Harvard University and Harvard Medical • Professor Connie Cepko is Professor at Harvard Medical School as well as at Semmelweis Medical School. Dr. Roska’s School. Professor Cepko works on the mechanisms that direct group studies the structure and function of the retina and development of the central nervous system of vertebrates and, in pioneered retina cell type specific optogenetic vision restoration. particular, on the vertebrate retina. Professor Cepko has produced • Professor José-Alain Sahel (Vice-Chairman of our Scientific seminal works in the mechanisms that lead to the death of Advisory Board) is chair the Institut de la Vision, a center of photoreceptors in the many inherited forms of human blindness. excel lence in ophthalmology assembling scientific teams (UPMC, INSERM and CNRS) as well as the French National • Dr. Serge Pcaud,i Ph.D., is director of research at the Institut Eye Hospital, featuring access to cohorts of wel l-diagnosed de la Vision in Paris. Over the last 15 years, Dr. Picaud has patients and a state-of-the-art Clinical Investigation Center. developed many cellular and animal models of different retinal diseases for assessing the efficacy of neuroprotection or other • Professor Jean Bennett (Vice-Chairman of our Scientific therapeutic strategies. Dr. Picaud thus developed the culture of Advisory Board) is Professor of Ophthalmology and Cel l post-mortem human retinal tissue, which provides the means to and Developmental Biology and a SeniorInvetasigtor in test AAV vectors efficacy on human retinal neurones. the F. M. Kirby Center for Molecular Ophthalmology at the University Of Pennsylvania School Of Medicine. Professor To our knowledge, as of the date of this Registration Document, Bennett also has an appointment as a Senior Investigator at the there are no conflicts of interest between the position of Center for Cellular and Molecular Therapeutics, The Children’s Dr. Botond Roska and Professor José-Alain Sahel in the Company Hospital of Philadelphia. and their position in FMI and Institut de la Vision, respectively. GENSIGHT BIOLOGICS – 2017 Registration Document– 131